219 - Safety and Immunogenicity of BNT166a, an Investigational Quadrivalent mRNA Mpox Vaccine

Presenting Author(s)

• LD

  Leela Davies, MD, PhD

  BioNTech US Inc
  Cambridge, Massachusetts, United States

  Slides

Co-Author(s)

• FB

  Frank Bähner, MD

  BioNTech SE
  Mainz, Hamburg, Germany
• 

  Saul N. Faust, FRCPCH PhD (he/him/his)

  Professor of Paediatric Immunology and Infectious Diseases
  University of Southampton and University Hospital Southampton NHS Foundation Trust
  Southampton, England, United Kingdom
• OB

  Olga Blokhina, MD

  BioNTech SE
  Mainz, Hamburg, Germany
• DB

  Donald Brandon, MD

  Medical Director
  California Research Foundation
  San Diego, CA, United States
• WS

  William B. Smith, MD

  Alliance for Multispecialty Research
  Knoxville, Tennessee, United States
• VC

  Vengalil Krishna K. Chatterjee, FRCP

  NIHR Cambridge Clinical Research Facility
  Cambridge, England, United Kingdom
• HH

  Hana Hassanin, MD, FRCP

  University of Surrey
  Guildford, England, United Kingdom
• 

  Tara M. Babu, MD, MSCI (she/her/hers)

  Acting Assistant Professor
  University of Washington
  Seattle, Washington, United States
• AZ

  Adam Zuiani, PhD

  BioNTech US Inc
  Cambridge, Massachusetts, United States
• TM

  Tim Müller, MSc

  Staburo GmbH
  Munich, Bayern, Germany
• AP

  Asaf Poran, PhD

  BioNTech US Inc
  Cambridge, Massachusetts, United States
• CB

  Claire Brittain, MSc

  BioNTech UK Ltd
  London, England, United Kingdom
• JH

  Jay W. Hooper, PhD

  United States Army Medical Research Institute of Infectious Diseases
  Fort Detrick, Maryland, United States
• EM

  Eric Mucker, PhD

  United States Army Medical Research Institute of Infectious Diseases
  Fort Detrick, Maryland, United States
• Rv

  Robbert G. van der Most, PhD

  BioNTech SE
  Mainz, Hamburg, Germany
• PA

  Pedro Alonso, MD, PhD

  BioNTech SE
  Mainz, Hamburg, Germany
• FM

  Federico Mensa, MD

  BioNTech
  Mainz, Rheinland-Pfalz, Germany